NCT05833022已完成不适用
Patient Characteristics and Treatment Patterns From Early Crizanlizumab Use in Real-world Setting: Preliminary Analysis From Select Sickle Cell Centers
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 297
- 试验地点
- 11
- 主要终点
- Percentage of patients who received sickle cell disease treatment (use of hydroxyurea, l-glutamine, chronic transfusion therapy, and voxelotor) during treatment with crizanlizumab
研究概览
简要总结
This was a retrospective cohort study using secondary data from member sites of the National Alliance of Sickle Cell Centers (NASCC) with at least five patients who initiated crizanlizumab. Patients who were prescribed crizanlizumab were included in the cohort.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 16 Years 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
结局指标
主要结局
Percentage of patients who received sickle cell disease treatment (use of hydroxyurea, l-glutamine, chronic transfusion therapy, and voxelotor) during treatment with crizanlizumab
时间窗: Up to 12 months
Percentage of patients who received sickle cell disease treatment (use of hydroxyurea, l-glutamine, chronic transfusion therapy, and voxelotor) prior to treatment with crizanlizumab
时间窗: Up to 12 months
次要结局
- Number of doses of crizanlizumab for patients who discontinued treatment with crizanlizumab(Up to 24 months)
- Number of sickle cell disease (SCD)-related hospitalizations(Up to 24 months)
- Number of patients who discontinued treatment with crizanlizumab(Up to 24 months)
- Reasons for early discontinuation of crizanlizumab treatment(Up to 24 months)
- Number of SCD-related emergency department (ED) visits(Up to 24 months)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
不适用
Real World Patient Characteristics and Treatment Patterns From Crizanlizumab Use: Preliminary Analysis From Select Sickle Cell CentersSickle Cell DiseaseNCT06662825Novartis376
已完成
不适用
Characteristics and Treatment Patterns of Patients With Sickle Cell Disease in Globin Research Network for Data and Discovery RegistrySickle Cell DiseaseNCT06662812Novartis1,665
已完成
不适用
Patients Characteristics, Treatment Pattern & Outcomes of Patients With Advanced, Recurrent or Metastatic Endometrial CarcinomaOncologyEndometrial CancerAdvanced CancerRecurrent CancerMetastatic CancerNCT05364905ARCAGY/ GINECO GROUP200
已完成
不适用
Treatment Patterns and Outcomes in Participants With Advanced Melanoma in Germany Using a German DatabaseAdvanced MelanomaNCT05426239Bristol-Myers Squibb1,008
已完成
不适用
Patient Characteristics, Associated Factors, and Clinical Outcomes of Prescribing Encorafenib and Binimetenib Versus Dabrafenib and Trametinib Among BRAF v600 Mutated Metastatic Melanoma PatientsBRAF v600 Mutated Metastatic MelanomaNCT05806268Novartis Pharmaceuticals214